As viruses tend to produce limited amounts of protein, nature requires that these proteins be extremely potent.  In preclinical and clinical testing, Viron's protein candidates have demonstrated potent anti-inflammatory properties in the picoMolar range and below.  Extremely high potency is important to derive favorable dosing schemes and support a favorable safety profile as very small amounts of drug substance are needed to achieve the desired pharmaceutical effect.

Viron's lead product, VT-111, has demonstrated potent efficacy in models where inflammation plays a key role (e.g. angioplasty plus stent placement, solid organ transplantion, and vascular bypass). 

Viron reported positive results from a Phase IIa study evaluating VT-111 for the treatment of vascular inflammation in patients with Acute Coronary Syndrome during the Scientific Sessions of the American Heart Association (AHA) 2009 conference. The results demonstrated that VT-111 significantly reduces key cardiac enzymes at multiple time points after stent placement. VT-111 met both primary and secondary endpoints of the trial, which was designed to evaluate the safety and biological activity of VT-111 in Acute Coronary Syndrome (ACS) patients receiving coronary stents.

In preclinical cardiovascular models, VT-111 has demonstrated a powerful ability to reduce monocyte infiltration into vasculature at sites of angioplasty/stent placement.  In numerous preclinical tranplant models, VT-111 effectively prevents over-reaction of the inflammatory cell response in the first 10 days post solid organ transplantation.